Keyphrases
Type 2 Diabetic Patients
100%
Type 2 Diabetes Mellitus (T2DM)
94%
Glucagon-like
51%
Glucose-dependent Insulinotropic Polypeptide
40%
Carbohydrates
37%
Hypoglycemia
31%
High-protein Diet
30%
Insulin
29%
Randomized Controlled Trial
25%
Metformin
22%
Insulin Therapy
21%
Placebo
21%
Glucagon
21%
Hemoglobin A1c (HbA1c)
21%
Low-carbohydrate Diet
20%
Weight Loss
20%
Diabetic
20%
Incretin Effect
19%
Insulinotropic Effects
19%
β-cell Function
19%
Insulin Secretion
18%
Chronic Pancreatitis
18%
Copenhagen
16%
Clinical Practice
14%
Diabetes Diet
14%
Insulin Independence
14%
Blood Glucose
14%
Metformin Therapy
13%
Diabetes
13%
Dietary Carbohydrate Restriction
13%
Incretin Hormones
13%
Exenatide Once Weekly
11%
Liraglutide
11%
Insulin Analogues
11%
Insulin Response
11%
High Protein
11%
Glycemic Control
10%
Carotid Intima-media Thickness (cIMT)
10%
Dysglycemia
10%
Insulin Dose
10%
Area under the Curve
10%
Normal Glucose Tolerance
9%
Cardiovascular Events
9%
Glucose Effect
9%
β-cell Secretory Capacity
8%
Basal Insulin
8%
Insulin Resistance
8%
B Cells
8%
Injectable Therapies
7%
Body Mass Index
7%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
80%
Patient with Type 2 Diabetes
58%
Glucagon Like Peptide 1
38%
Gastric Inhibitory Polypeptide
35%
Protein Diet
32%
Diabetes
32%
Meal
24%
Beta Cell
24%
Glycon
23%
Insulin Release
23%
Placebo
21%
Randomized Controlled Trial
21%
Diabetes Mellitus
21%
Cell Function
20%
Incretin
19%
Carbohydrate Diet
18%
Body Weight
16%
Insulin Derivative
14%
Glucagon
14%
Hemoglobin A1c
13%
Cardiovascular System
13%
Chronic Pancreatitis
12%
Insulin Response
11%
Insulin Like Activity
10%
Intima-Media Thickness
10%
Blood Glucose
10%
Hypoglycemia
10%
Body Mass Index
9%
B Cell
8%
Gastrointestinal Hormone
8%
Secretion (Process)
7%
Glucose Tolerance
7%
Secondary Diabetes
7%
Insulin Resistance
7%
Triacylglycerol
7%
Glycemic Control
7%
C-Peptide
7%
Fatty Acid
6%
Fatty Liver
6%
Dipeptidyl Peptidase-4 Inhibitor
6%
Cardiovascular Disease
6%
Liraglutide
5%
Impaired Glucose Tolerance
5%
Satiety
5%
Oral Glucose Tolerance Test
5%
Sitagliptin
5%
Adverse Event
5%
